Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Access qualified and experienced investigators to partner with on your clinical trials
Get coverage of the latest pharmaceutical business developments, and historical metrics on financing, licensing, partnership, and acquisition.
Our trusted Pharma Intelligence brands
Thought leadership, Pharma Marketing Solutions
13 Sep 2021
Account-based marketing/engagement (ABM/ABE): this customer-centric, cross-functional approach to delivering clients and prospective clients superior marketing campaigns has become increasingly popular.
Topic Market Intelligence
Biomedtracker, Meddevicetracker
27 Aug 2021
What major drug catalysts and events can you expect to see in the months ahead? Download your free extract from the Q3 2021 Outlook Report and infographic to find out. Shape your strategy with your inside look at what’s to come.
Topic Drug Review
Medtech Insight
By Shawn M. Schmitt 26 Aug 2021
Baxter says customers complained of “multiple pumps within their fleets” encountering system errors after they made changes to their network configuration and server systems. It’s the second software-related setback for the device maker in recent weeks.
Pharma Consulting
20 Aug 2021
We’re excited to share our latest Q2 report on Gene, Cell, & RNA Therapies with The American Society of Gene & Cell Therapy (ASGCT). This newest report calls out some important updates and changes within the Gene, Cell, & RNA Therapy Landscape.
Topic Cell & Gene Therapy
Medtech Insight
By Shawn M. Schmitt 20 Aug 2021
The Safety Scalpel N11 is a component of Cardinal Health’s Argyle UVC Insertion Tray, which was recalled because it didn’t include the scalpel’s instructions for use. The recall has been labeled high-risk class I by the US FDA.
Generics Bulletin
19 Aug 2021
India leads the ways with the highest number of approved biosimilars.
Topic Clinical Trials Biosimilars
In Vivo
18 Aug 2021
Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.
Scrip
By Dexter Yan 18 Aug 2021
Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.
Pharma Marketing Solutions, Lead generation, Pharma Brand Aw...
17 Aug 2021
As the world’s leading provider of news, analysis, and data for the pharmaceutical, generics, consumer healthcare, and medtech markets, we know your target audience – they’re our subscribers.
Topic Market Intelligence
HBW Insight
By Ryan Nelson 17 Aug 2021
The agency’s recent request for contractor quotes cites infants and children, people of color, and immunosuppressed individuals among users whose “unique biological characteristics” could require special consideration in the evaluation of cosmetic ingredients. The FDA also is interested in accounting for unique physicochemical aspects of ingredients such as engineered nanomaterials.
In Vivo
By William Masters 16 Aug 2021
Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.
Pink Sheet
By Sue Sutter 16 Aug 2021
After repeatedly advising against tivozanib NDA submission on the basis of interim overall survival data that suggested a negative trend, agency ultimately concluded the final analysis did not suggest a detrimental effect in third-line renal cell carcinoma even though median overall survival was shorter than for the comparator agent, Bayer’s Nexavar.
Scrip
By Ian Haydock 16 Aug 2021
In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.
Pharmaprojects, Citeline
By Ian Lloyd 13 Aug 2021
Our world was disrupted at warp speed during 2020. Are you ready to gain a deeper understanding of the year that changed our perceptions of possible?
HBW Insight
By Malcolm Spicer 13 Aug 2021
Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.
Scrip
17 Sep 2021
Generics Bulletin
17 Sep 2021
Generics Bulletin
17 Sep 2021
Scrip
17 Sep 2021
HBW Insight
17 Sep 2021
Generics Bulletin
17 Sep 2021
HBW Insight
17 Sep 2021
Generics Bulletin
17 Sep 2021
Medtech Insight
17 Sep 2021
Medtech Insight
17 Sep 2021
Generics Bulletin
16 Sep 2021
Pink Sheet
16 Sep 2021
Generics Bulletin
16 Sep 2021
Medtech Insight
16 Sep 2021
HBW Insight
16 Sep 2021
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
20 Sep 2021 , 14:00
Conference
14 Oct 2021 , 18:00
Awards
10 Nov 2021 , 18:00
Awards
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
